Loading clinical trials...
Loading clinical trials...
Multicentre Phase 2 Trial to Evaluate the Efficacy of Ruxolitinib in Steroid-refractory Acute Multicenter, Randomized Phase 2 Trial to Determine the Response Rate of Ruxolitinib and Best Available Treatment (BAT) Versus BAT in Steroid-refractory Acute Graft-versus-Host Disease (aGvHD)
Conditions
Interventions
Experimental intervention
Standard treatment
Locations
11
Germany
Charité - Universitätsmedizin Berlin
Berlin, Germany
Universitätsklinikum Bonn
Bonn, Germany
Universitätsklinikum Köln
Cologne, Germany
Universitätsklinikum Dresden
Dresden, Germany
University Medical Center
Freiburg im Breisgau, Germany
Universitätsklinikum Hamburg Eppendorf
Hamburg, Germany
Start Date
June 29, 2017
Primary Completion Date
November 15, 2019
Completion Date
November 15, 2019
Last Updated
December 2, 2019
NCT00106925
NCT06450925
NCT04337515
NCT06681922
NCT03369353
NCT03842696
Lead Sponsor
Prof. Dr. Nikolas von Bubnoff
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions